Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis

Annals of the American Thoracic Society

Volumn 12, Issue 3, 2015, Pages 303-312

  Rennard, Stephen I ^a   Locantore, Nicholas ^b   Delafont, Bruno ^c   Tal Singer, Ruth ^b   Silverman, Edwin K ^d   Vestbo, Jørgen ^e,f   Miller, Bruce E ^b   Bakke, Per ^g   Celli, Bartolomé ^d   Calverley, Peter M A ^h   Coxson, Harvey ⁱ   Crim, Courtney ^b   Edwards, Lisa D ^b   Lomas, David A ^j   Macnee, William ^k   Wouters, Emiel F M ^l   Yates, Julie C ^b   Coca, Ignacio ^m   Agustí, Alvar ^m,n  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF BERGEN   (Norway)

^h UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Chronic obstructive pulmonary disease; Cluster analysis; Longitudinal outcomes

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLASSIFICATION ALGORITHM; CLINICAL FEATURE; CLUSTER ANALYSIS; COHORT ANALYSIS; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; REPRODUCIBILITY; SYMPTOM ASSESSMENT;

EID: 84964298566     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201403-125OC     Document Type: Article

References (34)

1. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
2. Shapiro SD, Reilly JJJ, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Broaddus VC, Martin TR, King TE Jr., Schraufnagel DE, Murray JF, Nadel JA, editors. Textbook of respiratory medicine. 5th ed. Philadelphia, PA: Saunders; 2010. pp. 919-967.
3. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
4. Everitt BS, Landau S, Leese M, Stahl D. Cluster analysis. 5th Edition. Hoboken NJ: John Wiley and Sons; 2011.
5. Therneau T, Atkinson E. Technical report series no. 61, AItRPUtRRDoHSR, Mayo Clinic, Rochester, Minnesota, 1997. An introduction to recursive partitioning using the RPART routines. Rochester, MN: Department of Health Science Research, Mayo Clinic; 1997.
6. Pistolesi M, Camiciottoli G, Paoletti M, Marmai C, Lavorini F, Meoni E, Marchesi C, Giuntini C. Identification of a predominant COPD phenotype in clinical practice. Respir Med 2008;102:367-376.
7. Cho MH, Washko GR, Hoffmann TJ, Criner GJ, Hoffman EA, Martinez FJ, Laird N, Reilly JJ, Silverman EK. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation. Respir Res 2010;11:30.
8. Garcia-Aymerich J, Gómez FP, Benet M, Farrero E, Basagaña X, Gayete À, Paré C, Freixa X, Ferrer J, Ferrer A, et al.; PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-437.
9. Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, Coolen J, Troosters T, Decramer M, Janssens W. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS ONE 2012;7:e51048.
10. Burgel PR, Roche N, Paillasseur JL, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Caillaud D; INITIATIVES BPCO Scientific Committee. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012;40:495-496.
11. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, Court-Fortune I, Perez T, Carré P, Roche N; Initiatives BPCO Scientific Committee. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010;36:531-539.
12. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, Van Empel VP, Bruijnzeel PL, Rutten EP, Op't Roodt J, Wouters EF, Franssen FM. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
13. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al.; ECLIPSE investigators. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE). Eur Respir J 2008;31:869-873.
14. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
15. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013;1:129-136.
16. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agustí A, Bakke PS, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013;187:382-386.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S121.
18. Patel BD, Coxson HO, Pillai SG, Agustí AG, Calverley PM, Donner CF, Make BJ, Müller NL, Rennard SI, Vestbo J, et al.; International COPD Genetics Network. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:500-505.
19. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
20. Breiman and Cutler's random forests for classification and regression [last updated 2012; accessed 2014 Feb. 3]. Available from: http://stat-www.berkeley.edu/users/breiman/RandomForests
21. Breiman L. Random forests. Mach Learn 2001;45:5-32.
22. Shi T, Horvath S. Unsupervised learning with random forest predictors. J Comput Graph Stat 2006;15:118-138.
23. McDonald R. Factor analysis and related methods. New Jersey: Lawrence Erlbaum Associates; 1985.
24. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) Study Investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
25. Castaldi PJ, Dy J, Ross J, Chang Y, Washko GR, Curran-Everett D, Williams A, Lynch DA, Make BJ, Crapo JD, et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax 2014;69:415-422.
26. Gremeaux V, Troisgros O, Benaïm S, Hannequin A, Laurent Y, Casillas JM, Benaïm C. Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch Phys Med Rehabil 2011;92:611-619.
27. Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, et al. Six-minutewalk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-1237.
28. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-356.
29. Holland AE, Nici L. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:335-336.
30. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995;107(Suppl) 187S-193S.
31. Wijkstra PJ, Ten Vergert EM, Van Der Mark TW, Postma DS, Van Altena R, Kraan J, Koëter GH. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994;49:468-472.
32. Chuang ML, Lin IF, Wasserman K. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. Respir Med 2001;95:618-626.
33. Krane M, Griese M. Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis. Eur Respir J 2003;22:592-595.
34. Sin DD, Man SF, Marciniuk DD, Ford G, Fitz Gerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, et al.; ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207-1214.